<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-2252</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОТ РЕДАКЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>FROM EDITOR</subject></subj-group></article-categories><title-group><article-title>«ФАРМ-АКТИВ ПРО» – платформа надежности</article-title><trans-title-group xml:lang="en"><trans-title>"PHARM-AKTIV PRO" – a reliability platform</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рекламная</surname><given-names>статья</given-names></name><name name-style="western" xml:lang="en"><surname>Sponsored</surname><given-names>Article</given-names></name></name-alternatives></contrib></contrib-group><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>03</day><month>12</month><year>2025</year></pub-date><volume>14</volume><issue>4</issue><fpage>30</fpage><lpage>30</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Рекламная с., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Рекламная с.</copyright-holder><copyright-holder xml:lang="en">Sponsored a.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/2252">https://www.pharmjournal.ru/jour/article/view/2252</self-uri><abstract><p>Компания «ФАРМ-АКТИВ ПРО» обеспечивает системный подход к оснащению фармацевтических и лабораторных производств. В нашем понимании поставка – это полный цикл, от проектирования и выбора оптимальных решений до ввода в эксплуатацию, квалификации и сопровождения в течение всего жизненного цикла. Все – с учетом требований регистрации лекарственных средств, валидности процессов, контроля качества и регуляторной совместимости.</p></abstract><trans-abstract xml:lang="en"><p>PHARM-AKTIV PRO provides a comprehensive approach to equipping pharmaceutical and laboratory facilities. We understand supply as a full cycle, from design and selection of optimal solutions to commissioning, qualification, and support throughout the entire lifecycle. All in accordance with drug registration requirements, process validity, quality control, and regulatory compliance.</p></trans-abstract><funding-group><funding-statement xml:lang="ru">Авторы подготовили статью при финансовой поддержке  компании «ФАРМ-АКТИВ ПРО»</funding-statement><funding-statement xml:lang="en">The authors prepared the article with the financial support of the company "PHARM-AKTIV PRO"</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
